TRINSERRA
DEAD

Serial Number

88893369

Owner

Xentria, Inc.

Attorney

Eric R. Moran

Filing Date

Apr 29, 2020

Add to watchlist:

No watchlists yet
View on USPTO

TRINSERRA Trademark

Serial Number: 88893369

TRINSERRA is a trademark filed by Xentria, Inc. on April 29, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently no longer active.

Owner Contact Info

Xentria, Inc. (12 trademarks)

8700 West Bryn Mawr Avenue
Chicago, IL 60631

Entity Type: 03

Trademark Details

Filing Date

April 29, 2020

Registration Date

Not Registered

Published for Opposition

August 31, 2021

Goods & Services

house mark for a full line of biologic, biosimilar, and pharmaceutical preparations; house mark for a full line of biologics; house mark for a full line of biosimilars; house mark for a full line of pharmaceuticals; house mark for a full line of biologic, biosimilar, and pharmaceutical products; biologic, biosimilar, and pharmaceutical preparations for the treatment of bone disease; biologic, biosimilar, and pharmaceutical preparations for use in the treatment of oncological and metabolic diseases and disorders, and complications associated therewith; biologic, biosimilar, and pharmaceutical preparations for the treatment of diabetes; biologic, biosimilar, and pharmaceutical preparations for treatment and prevention of autoimmune diseases and autoimmune disorders; biologic, biosimilar, and pharmaceutical oncology preparations; anti-inflammatories; biologic, biosimilar, and pharmaceutical preparations for the treatment of immune system related diseases and disorders; biologic, biosimilar, and pharmaceutical preparations for use in dermatology; biologic, biosimilar, and pharmaceutical preparations for use in rheumatology; biologic, biosimilar, and pharmaceutical preparations, namely, anti-interleukin-6 (IL-6) receptor monoclonal antibody for the treatment of disease caused by IL-6 production; biologic, biosimilar, and pharmaceutical preparations, namely, biopharmaceuticals based on human monoclonal antibodies for the treatment of immune and inflammatory diseases and disorders

providing medical information; providing health information

research and development of biologics, biosimilars, and pharmaceuticals; providing information in the field of scientific and medical research related to biologics, biosimilars, and pharmaceuticals

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Nov 28, 2022 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Nov 28, 2022 ABN6
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 22, 2022 EXRA
SOU EXTENSION 1 GRANTED
Apr 20, 2022 EX1G
SOU EXTENSION 1 FILED
Apr 20, 2022 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 20, 2022 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Oct 26, 2021 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 31, 2021 NPUB
PUBLISHED FOR OPPOSITION
Aug 31, 2021 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 11, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 27, 2021 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 26, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 26, 2021 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Jul 26, 2021 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 29, 2021 GNFN
FINAL REFUSAL E-MAILED
Jan 29, 2021 GNFR
FINAL REFUSAL WRITTEN
Jan 29, 2021 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 23, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 22, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 22, 2021 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 23, 2020 GNRN
NON-FINAL ACTION E-MAILED
Jul 23, 2020 GNRT
NON-FINAL ACTION WRITTEN
Jul 23, 2020 CNRT
ASSIGNED TO EXAMINER
Jul 23, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 12, 2020 NWOS
NEW APPLICATION ENTERED
May 2, 2020 NWAP